Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$$$$$ 1.50 Weeeeeeeee $$$$$$$$$$ Thank You Lord Amen, Happy Thanksgiving $$$$$
Told ya to load all you can from 1.04 Friday BOOOOOOOM!! $$$$
Go Full Blast Buying now from 1.18 - 1.19 or get left behind and cry above 1.30 $$$$ BOOM!!! $$$
Lock your shares now from $3.00 - 3.50 For The January Effect Explosion!! BOOM $$$$
Dump that ALPP Load all you can here, Its about to Explode!!! $$$$ BOOM $$$$
This looks good ALPPoh 8k letting you know buddy. no inbox .bid up early 20%. Just giving you a heads up
Loaded All I can Friday, Huge News Pre-Market!!! Lock your shares now @ $3.50 $$$$
* * $VSTM Video Chart 11-22-2019 * *
Link to Video - click here to watch the technical chart video
Up 24% on 12 million shares. Over 12 times average volume on no news. What the check triggered that? Short squeeze by big buyer coming in? Dang if I didn't miss that I was thinking of adding off that bottom. Leaked news, just a big buyer coming in Or a big short covering? Head scratcher for sure.
VSTM~1.04 SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Verastem, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
92337C104
(CUSIP Number)
October 24, 2019
(Date of event which requires filing of this statement)
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
¨
Rule 13d-1(b)
x
Rule 13d-1(c)
¨
Rule 13d-1(d)
(Page 1 of 8 Pages)
______________________________
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 92337C104
13G
Page 2 of 8 Pages
1
NAMES OF REPORTING PERSONS
Highbridge Capital Management, LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) ¨
3
SEC USE ONLY
4
CITIZENSHIP OR PLACE OF ORGANIZATION
State of Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5
SOLE VOTING POWER
0
6
SHARED VOTING POWER
4,065,183 shares of Common Stock issuable upon conversion of convertible notes
7
SOLE DISPOSITIVE POWER
0
8
SHARED DISPOSITIVE POWER
4,065,183 shares of Common Stock issuable upon conversion of convertible notes
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,065,183 shares of Common Stock issuable upon conversion of convertible notes
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
¨
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.18%
12
TYPE OF REPORTING PERSON
IA, OO
CUSIP No. 92337C104
13G
Page 3 of 8 Pages
1
NAMES OF REPORTING PERSONS
1992 Tactical Credit Master Fund, L.P.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) ¨
3
SEC USE ONLY
4
CITIZENSHIP OR PLACE OF ORGANIZATION
State of Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5
SOLE VOTING POWER
0
6
SHARED VOTING POWER
4,065,183 shares of Common Stock issuable upon conversion of convertible notes
7
SOLE DISPOSITIVE POWER
0
8
SHARED DISPOSITIVE POWER
4,065,183 shares of Common Stock issuable upon conversion of convertible notes
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,065,183 shares of Common Stock issuable upon conversion of convertible notes
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
¨
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.18%
12
TYPE OF REPORTING PERSON
PN
CUSIP No. 92337C104
13G
Page 4 of 8 Pages
Item 1(a).
NAME OF ISSUER:
The name of the issuer is Verastem, Inc. (the "Company").
Item 1(b).
ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
The Company's principal executive offices are located at 117 Kendrick Street, Suite 500, Needham, MA 02494.
Item 2(a).
NAME OF PERSON FILING:
Item 2(b).
ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Item 2(c).
CITIZENSHIP:
This statement is filed by:
(i)
Highbridge Capital Management, LLC
277 Park Avenue, 23rd Floor
New York, New York 10172
Citizenship: State of Delaware
(ii)
1992 Tactical Credit Master Fund, L.P.
277 Park Avenue, 23rd Floor
New York, New York 10172
Citizenship: State of Delaware
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
Item 2(d).
TITLE OF CLASS OF SECURITIES:
Common Stock, par value $0.0001 per share (the "Common Stock").
Item 2(e).
CUSIP NUMBER:
92337C104
Item 3.
IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
(a)
¨
Broker or dealer registered under Section 15 of the Act,
(b)
¨
Bank as defined in Section 3(a)(6) of the Act,
(c)
¨
Insurance Company as defined in Section 3(a)(19) of the Act,
(d)
¨
Investment Company registered under Section 8 of the Investment Company Act of 1940,
(e)
¨
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
CUSIP No. 92337C104
13G
Page 5 of 8 Pages
(f)
¨
Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
(g)
¨
Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
(h)
¨
Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
(i)
¨
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
(j)
¨
A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
(k)
¨
Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
specify the type of institution:____________________________________
Item 4.
OWNERSHIP.
(a) Amount beneficially owned:
As of the date hereof, (i) Highbridge Capital Management, LLC, as the trading manager of 1992 Tactical Credit Master Fund, L.P., may be deemed to be the beneficial owner of the 4,065,183 shares of Common Stock issuable upon conversion of convertible notes held by 1992 Tactical Credit Master Fund, L.P. and (ii) 1992 Tactical Credit Master Fund, L.P. may be deemed to be the beneficial owner of the 4,065,183 shares of Common Stock issuable upon conversion of convertible notes held by it.
(b) Percent of class:
The percentages used herein and in the rest of this Schedule 13G are calculated based upon 74,349,659 shares of Common Stock reported to be outstanding, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019 filed with the Securities and Exchange Commission on October 30, 2019, and assumes the conversion of the convertible notes reported herein. Therefore, as of the date hereof, (i) Highbridge Capital Management, LLC may be deemed to beneficially own approximately 5.18% of the outstanding shares of Common Stock and (ii) 1992 Tactical Credit Master Fund, L.P. may be deemed to beneficially own approximately 5.18% of the outstanding shares of Common Stock.
The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the shares of Common Stock issuable upon conversion of the convertible notes held by 1992 Tactical Credit Master Fund, L.P.
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote
0
CUSIP No. 92337C104
13G
Page 6 of 8 Pages
(ii) Shared power to vote or to direct the vote
See Item 4(a)
(iii) Sole power to dispose or to direct the disposition of
0
(iv) Shared power to dispose or to direct
the disposition of
See Item 4(a)
Item 5.
OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
Not applicable.
Item 6.
OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Not applicable.
Item 7.
IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
Not applicable.
Item 8.
IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable.
Item 9.
NOTICE OF DISSOLUTION OF GROUP.
Not applicable.
Item 10.
CERTIFICATION.
Each Reporting Person hereby makes the following certification:
By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
CUSIP No. 92337C104
13G
Page 7 of 8 Pages
SIGNATURES
After reasonable inquiry and to the best of our knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.
DATED: November 4, 2019
HIGHBRIDGE CAPITAL MANAGEMENT, LLC
By:
/s/ John Oliva
Name:
John Oliva
Title:
Managing Director
1992 TACTICAL CREDIT MASTER FUND, L.P.
By:
Highbridge Capital Management, LLC
its Trading Manager
By:
/s/ John Oliva
Name:
John Oliva
Title:
Managing Director
CUSIP No. 92337C104
13G
Page 8 of 8 Pages
EXHIBIT 1
JOINT FILING AGREEMENT
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
DATED: November 4, 2019
HIGHBRIDGE CAPITAL MANAGEMENT, LLC
By:
/s/ John Oliva
Name:
John Oliva
Title:
Managing Director
1992 TACTICAL CREDIT MASTER FUND, L.P.
By:
Highbridge Capital Management, LLC
its Trading Manager
By:
/s/ John Oliva
Name:
John Oliva
Title:
Managing Director
VSTM 1.03,,,,nice volume going sale will stop and monsta run ahead
VSTM 1.05 chart crazyy oversold,gonna bounce crazy
VSTM hit new 52w low at 1.035 today
VSTM 1.03 NEWSS Item 1.01 Entry into a Material Definitive Agreement
Exchange and Subscription Agreements
On November 12, 2019, Verastem, Inc. (the “Company”) entered into privately negotiated agreements (the “Agreements”) with a limited number of investors who are accredited investors (within the meaning of Rule 501 promulgated under the Securities Act of 1933, as amended (the “Securities Act”)) and/or qualified institutional buyers (as defined in Rule 144A under the Securities Act) who are holders of the Company’s 5.00% Convertible Senior Notes due 2048 (the “Existing Notes”) to exchange approximately $114.3 million aggregate principal amount of Existing Notes for approximately $62.9 million aggregate principal amount of newly issued 5.00% Convertible Senior Second Lien Notes due 2048 (the “Notes”). Each exchanging investor will also receive a cash payment equal to 10.0% of the principal amount of Existing Notes exchanged, together with together with accrued and unpaid interest on the Existing Notes (plus, if applicable, an adjustment in lieu of issuing fractional Notes). The issuance of the Notes is expected to close on November 14, 2019, subject to customary closing conditions. The Notes will be issued pursuant to an indenture by and between the Company and Wilmington Trust, National Association, as trustee and collateral agent (the “Indenture”).
The Company will have the right, exercisable at its option, to cause all Notes then outstanding to be converted automatically if the “Daily VWAP” (as defined in the Indenture) per share of the Company’s common stock equals or exceeds 121% of the conversion price on each of at least 20 “VWAP Trading Days” (as defined in the Indenture), whether or not consecutive, during any 30 consecutive VWAP Trading Day period commencing on or after the date the Company first issued the Notes.
The initial conversion rate for the Notes is 606.0606 shares of the Company’s common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $1.65 per share, representing an approximately 52.8% premium to the last reported sale price of $1.08 per share of the Company’s common stock on November 11, 2019, as reported on the Nasdaq Global Market. The conversion rate is subject to adjustment from time to time upon the occurrence of certain events, including, but not limited to, the issuance of stock dividends and payment of cash dividends, but will not be adjusted for any accrued and unpaid interest.
Prior to November 1, 2022, the Company will not have the right to redeem the Notes. On or after November 1, 2022, the Company may elect to redeem the Notes, in whole or in part, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any.
Unless the Company has previously called all outstanding Notes for redemption, the Notes will be subject to repurchase by the Company at the holders’ option on each of November 1, 2023, November 1, 2028, November 1, 2033, November 1, 2038 and November 1, 2043 (or, if any such date is not a business day, on the next business day) at a cash repurchase price equal to the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any.
If a “Fundamental Change” (as defined in the Indenture) occurs at any time, subject to certain conditions, holders may require the Company to purchase all or any portion of their Notes at a purchase price equal to 100% of the principal amount of the Notes to be purchased, plus accrued and unpaid interest, if any, to, but excluding, the “Fundamental Change Repurchase Date” (as defined in the Indenture). If a “Make-Whole Fundamental Change” (as defined in the Indenture) occurs on or before November 1, 2022 and a holder elects to convert its Notes in connection with such Make-Whole Fundamental Change, such holder may be entitled to an increase in the conversion rate in certain circumstances as set forth in the Indenture.
Upon conversion of the Notes, holders will receive a cash payment equal to the accrued and unpaid interest on the converted Notes. In addition, if the Notes are converted with a conversion date that is on or prior to November 1, 2020 (or, if such date is not a business day, on the next business day), other than in connection with the Company’s exercise of the “Company Mandatory Conversion Right” (as defined in the Indenture), then the consideration due upon any such conversion will also include a cash interest make-whole payment for all future scheduled interest payments on the converted Notes through November 1, 2020.
The Notes are the Company’s senior, secured obligations and will be senior in right of payment to the Company’s future indebtedness that is expressly subordinated in right of payment to the Notes, and equal in right of payment with the Company’s existing and future indebtedness that is not so subordinated. The Notes are structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries.
The Indenture includes a grant of a security interest in and second lien on the assets of the Company securing indebtedness issued under its existing senior secured credit facility, as well as customary covenants, and sets forth certain events of default after which the Notes may be declared immediately due and payable and sets forth certain types of bankruptcy or insolvency events of default involving the Company or certain of its subsidiaries after which the Notes become automatically due and payable.
In connection with the Exchange, the Company intends to enter into an amendment to its existing senior secured credit facility (the “Credit Facility Amendment”) with Hercules Capital, Inc., as agent (in such capacity, “Agent”) for itself and the other lenders, pursuant to which Agent consents to (i) the Company’s use of cash to facilitate the Exchange and (ii) the issuance of the Notes, subject to the liens securing such Notes being subordinated to the liens in favor of Agent and to the imposition of certain liquidity thresholds and financial covenants.
The foregoing description of the Agreements does not purport to be complete and is qualified in its entirety by reference to the form of the Agreements, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing descriptions of the Credit Facility Amendment and Indenture do not purport to be complete and are qualified in their entirety by reference to the Credit Facility Amendment and the Indenture, which will be filed as exhibits to future filings by the Company with the Securities and Exchange Commission pursuant to the Securities Exchange Act or 1934, as amended (the “Exchange Act”).
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
The information set forth under Item 1.01 is incorporated into this Item 2.03 by reference.
Item 3.02 Unregistered Sales of Equity Securities
As described in Item 1.01 of this Current Report on Form 8-K, which is incorporated herein by reference, on November 14, 2019, the Company expects to issue the Notes. The Company will issue the Notes in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act. Any shares of common stock issued upon conversion of the Notes will be issued pursuant to Section 3(a)(9) of the Securities Act as an exchange with existing security holders. Based on the initial maximum conversion rate of 925.9259 shares of common stock per $1,000 principal amount of notes, a maximum of approximately 58.2 million shares of common stock are initially issuable upon conversion of the Notes. The offer and sale of the Notes and the shares of common stock issuable upon conversion of the Notes have not been, and will not be, registered under the Securities Act.
Item 7.01 Other Events.
On November 12, 2019, the Company issued a press release announcing the note exchange transactions. A copy of the press release is attached hereto as Exhibit 99.1. The information in this report, including Exhibits 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act or in any filing under the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit No.
Description
10.1
Form of Exchange Agreement, dated as of November 12, 2019, among Verastem, Inc. and each investor party thereto.
99.1
Press Release dated November 12, 2019.
The breakout was yesterday
* * $VSTM Video Chart 10-23-2019 * *
Link to Video - click here to watch the technical chart video
* * $VSTM Video Chart 10-03-2019 * *
Link to Video - click here to watch the technical chart video
“The data presented at SOHO this year highlight the outcomes from the Phase 3 DUO study in the labeled indication, as well as supplemental lymphocytosis data, and continue to support its ongoing use in patients with relapsed or refractory CLL/SLL,” said Hagop Youssoufian, MSc, M.D., Head of Medical Strategy at Verastem Oncology. “These findings not only support the ongoing use of duvelisib in its labeled indication for patients with relapsed or refractory CLL/SLL, but they also suggest that therapy with duvelisib may offer promise warranting further investigation in patients with refractory MZL, for whom limited treatment options exist.”
I added another 1000 shares at these give away prices
Something causing a 10% spike today. I wonder if it is anything Fundamental. I am guessing we will see Claytrader making a chart later today based on TA
Dr. Abedin on PI3K Inhibitors in CLL
Sameem Abedin, MD
Published: Monday, Aug 12, 2019
https://www.onclive.com/onclive-tv/dr-abedin-on-pi3k-inhibitors-in-cll
Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses the use of PI3K inhibitors in the treatment of patients with chronic lymphocytic leukemia (CLL).
There are two approved PI3K inhibitors in CLL: duvelisib (Copiktra) and idelalisib (Zydelig). In 2018, the FDA approved duvelisib for the treatment of patients with relapsed/refractory CLL based on results from the phase III DUO study. In the trial, patients with relapsed/refractory CLL who had received ≥2 prior lines of therapy experienced a 60% reduction in the risk of disease progression or death versus ofatumumab (Arzerra).
In 2014, idelalisib was approved for use in combination with rituximab (Rituxan) in the relapsed/refractory setting based on data from the phase III Study 116 trial (NCT01539512). The trial was stopped early due to the dramatic improvement in progression-free survival (PFS) with the combination. At 24 weeks, the PFS rate of PFS was 93% in the combination arm and 46% in the rituximab-alone arm. The agents have slightly different mechanisms of action, and duvelisib has more immune properties, says Abedin.
In terms of administration, duvelisib is given as monotherapy, whereas idelalisib is given in combination with rituximab. For patients, the ease of taking a pill may be preferable to the combination, according to Abedin.
Ian W. Flinn, MD, PhD, on CLL/SLL: Effect of Dose Modifications on Response to Duvelisib
https://www.jnccn360.org/cll/videos/effect-of-dose-modifications-on-response-to-duvelisib/
Reply1
Company Reports $3.0 Million in Net Product Revenues from COPIKTRA(R); Raises Product Revenue Guidance for 2019
Cash, Cash Equivalents and Short-Term Investments of $187.3 Million as of June 30, 2019
Earnings tomorrow after the bell, could be a big surprise UP.
* * $VSTM Video Chart 07-26-2019 * *
Link to Video - click here to watch the technical chart video
VSTM will break shortly
3.15 MA(200)
2.05 MA(100)
pm was good to me
doesnt have a crazy low float
It's certainly a step in the right direction. I buy calls long out, biotechs need time to evolve
I agree, but it is not a home run as our illustrious mod was suggesting.
The fact that they are about to create a revenue pipeline and that another company is willing to invest in their platform will increase revenue and decrease burn rate.
It's kind of investing 101 in the biotechs dude, this ain't a blue chip.
A niche market?....It is a drug therapy. If someone's life is at stake, why haven't they generated any domestic sales. Because the drug is the third option, when all other therapies have failed. Therefore it targets a very limited market, is not a cure, is extremely costly, and has very serious adverse and potentially fatal side effects. The drug has been available to physicians for 9 months. A partner is not the issue. Demand is just not there. As far as their pipeline goes, nothing can be expected near term. At a $38M burn rate per quarter, they will have to further dilute the stock to continue operations. Why do you think stock is at or near 52 week low? Even this news did not move the stock much.
Most certainly isn't, it's merely in the launching phase. Trying to get a foothold in a niche market without a major partner is darn near impossible.
This is only the start of something big.
Burn rate is way too high. $2 mln in revenues and $38 mln in net loss, they are running out of cash in 5 quarters. Only FDA approved drug is in competition with many others and covers only a limited population. They have had 9 months to market and sell it with near nothing results. Plus the treatment costs a staggering $11k/month. Company and stock doomed imo.
The company has over $200 million is cash, FDA approved drug, and more in the pipeline. This is the partnership they needed to help sell Copiktra.
This is ONLY the beginning.
DD. This drug was approved 9 months ago. It is not an end all cancer drug It is a last chance treatment after competitor's first and second line therapies don't work, hence it is labeled a third-line chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) treatment. The most recent PR stating that it for all oncology indications is a downright falsehood and deceptive to potential investors. Also the drug has serious adverse side effects. Copiktra was originally being developed by Infinity Pharmaceuticals and AbbVie. AbbVie walked away from the partnership in 2016 upon seeing the weak Phase II results.
This article says it all. Investors don't be deceived!
https://www.pharmaceutical-technology.com/comment/fda-approvals-copiktras-commercial-prospects/
Followers
|
60
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
796
|
Created
|
02/01/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |